이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PuraPharm 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Abraham Chan

최고 경영자

HK$6.2m

총 보상

CEO 급여 비율	65.3%
CEO 임기	12.5yrs
CEO 소유권	33.4%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	9yrs

최근 관리 업데이트

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

CEO 보상 분석

Abraham Chan 의 보수는 PuraPharm 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	HK$6m	HK$4m	-HK$106m
Sep 30 2023	n/a	n/a	-HK$112m
Jun 30 2023	n/a	n/a	-HK$118m
Mar 31 2023	n/a	n/a	-HK$119m
Dec 31 2022	HK$4m	HK$4m	-HK$120m
Sep 30 2022	n/a	n/a	-HK$147m
Jun 30 2022	n/a	n/a	-HK$174m
Mar 31 2022	n/a	n/a	-HK$148m
Dec 31 2021	HK$4m	HK$4m	-HK$122m
Sep 30 2021	n/a	n/a	-HK$45m
Jun 30 2021	n/a	n/a	HK$32m
Mar 31 2021	n/a	n/a	HK$32m
Dec 31 2020	HK$4m	HK$3m	HK$32m
Sep 30 2020	n/a	n/a	-HK$69m
Jun 30 2020	n/a	n/a	-HK$171m
Mar 31 2020	n/a	n/a	-HK$199m
Dec 31 2019	HK$3m	HK$1m	-HK$227m
Sep 30 2019	n/a	n/a	-HK$132m
Jun 30 2019	n/a	n/a	-HK$38m
Mar 31 2019	n/a	n/a	-HK$8m
Dec 31 2018	HK$2m	HK$1m	HK$21m
Sep 30 2018	n/a	n/a	HK$13m
Jun 30 2018	n/a	n/a	HK$6m
Mar 31 2018	n/a	n/a	HK$4m
Dec 31 2017	HK$4m	HK$4m	HK$2m

보상 대 시장: Abraham 의 총 보상 ($USD 794.84K )은 Hong Kong 시장( $USD 232.88K ).

보상과 수익: 회사가 수익성이 없는 동안 Abraham 의 보상이 증가했습니다.

CEO

Abraham Chan (63 yo)

12.5yrs

테뉴어

HK$6,205,000

보상

Mr. Yu Ling Chan, also known as Abraham, BASc C.Eng. MIStruct E. P.Eng., has been the Chief Executive Officer and Chairman of PuraPharm Corporation Limited. Mr. Chan has been a Director at PuraPharm Corpor...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yu Ling Chan	Founder	12.5yrs	HK$6.21m	33.42% HK$ 97.7m
Yee Wai Man	Executive Director	12.5yrs	HK$3.51m	0.044% HK$ 127.7k
Kwok Wah Ho	Independent Non-Executive Director	9yrs	HK$200.00k	0.0046% HK$ 13.3k
Bruce Robinson	Chairman of Scientific Advisory Committee	8.3yrs	데이터 없음	데이터 없음
Lap-Chee Tsui	Independent Non-Executive Director	9yrs	HK$200.00k	0.0046% HK$ 13.3k
Lim Kin Leung	Independent Non-Executive Director	9yrs	HK$200.00k	0.0046% HK$ 13.3k
Piu Chan	Member of Scientific Advisory Committee	no data	데이터 없음	데이터 없음
Rudolf Bauer	Member of Scientific Advisory Committee	no data	데이터 없음	데이터 없음
Song Ming Liang	Member of Scientific Advisory Committee	no data	데이터 없음	데이터 없음
Chi Ming Che	Member of Scientific Advisory Committee	2.4yrs	데이터 없음	데이터 없음
Kwok Keung Leung	Non-Executive Director	less than a year	HK$109.00k	데이터 없음

9.0yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: 1498 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

PuraPharm 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Recent updates

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령